Business
Niowave to supply Ac-225 for Ratio radiotherapy work
The agreement gives Ratio Therapeutics another cGMP Actinium-225 source for ongoing clinical trial activity and future targeted radiotherapeutic programs.
Company
Niowave
Business
Niowave Lansing site to scale Ac-225 supply by 2028
The Lansing, MI, site will house superconducting linear accelerators and radiochemistry systems to support scalable actinium-225 production, with completion expected in 2028.